|The full article is available to subscribers||Subscriber Login|
The FDA has approved eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist and delta-opioid receptor antagonist, for oral treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).
IBS — Symptoms of IBS can include abdominal pain, bloating, flatulence, diarrhea, and constipation. IBS is subtyped, according to the predominant bowel symptom, as IBS-D, IBS with constipation (IBS-C), mixed-type (IBS-M), or unclassified (IBS-U).
SOME DRUGS FOR IBS-D — The goal of IBS treatment is symptom control; dietary modifications may help improve symptoms of all subtypes of the disorder. For patients with IBS-D, antidiarrheals such as loperamide (Imodium A-D, and others) taken as needed may reduce stool urgency and frequency. In short-term clinical trials, the minimally absorbed antibiotic rifaximin (Xifaxan) was modestly more effective than placebo in... more
- Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea. Med Lett Drugs Ther 2015; 57:109.
- J Nee et al. Novel therapies in IBS-D treatment. Curr Treat Options Gastro 2015; 13:432.
- Drug Enforcement Administration, DOJ. Schedules of controlled substances: placement of eluxadoline into schedule IV. Final rule. Fed Regist 2015; 80:69861.
- JM Davenport et al. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol 2015; 55:534.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.